补虚通痹方治疗特发性肺间质纤维化疗效观察
|
摘要
目的:观察补虚通痹方治疗特发性肺间质纤维化(idiopathic pulmonary fibrosis,IPF)的疗效及安全性。方法:将IPF患者60例随机分为对照组和观察组各30例,对照组采用大剂量N-乙酰半胱氨酸及按需氧疗治疗,观察组采用补虚通痹方加按需氧疗治疗,疗程3个月,随访3个月。比较2组患者治疗前后6分钟步行距离、生活质量、中医证候积分、呼吸困难及咳嗽单项症状积分、肺功能变化情况。结果:观察组在延长6分钟步行距离、改善患者呼吸困难及咳嗽症状方面优于对照组,并且观察组能够稳定患者肺功能,未发现严重不良反应。结论:补虚通痹方能提高IPF患者活动耐力、改善患者呼吸困难及咳嗽症状并稳定患者肺功能,且安全性好。
Objective: To observe clinical effects and the safety of BuXu TongBi prescription in the treatment for idiopathic pulmonary fibrosis(IPF). Methods: Sixty patients were randomized into the control group and the observation group, 30 cases each group, the control group adopted large dose of N acetylcysteine(NAC) and ondemand oxygen therapy, the observation group used BuXu TongBi prescription and on-demand oxygen therapy, the course was three months, they were followed for three months. To compare six-minutes walking distance, life quality,TCM syndrome scores, the scores of difficult breathing and single item of cough and the changes of pulmonary function between both groups. Results: Th observation group was superior to the control group in prolonging six minutes walking distance, improving dyspnea and cough, and the observation group could stabilize pulmonary function, and no severe adverse reaction happened. Conclusion: BuXu TongBi prescription could raise exercise endurance of IPF patients, improve dyspnea and cough, stabilize pulmonary function with good safety.
Objective: To observe clinical effects and the safety of BuXu TongBi prescription in the treatment for idiopathic pulmonary fibrosis(IPF). Methods: Sixty patients were randomized into the control group and the observation group, 30 cases each group, the control group adopted large dose of N acetylcysteine(NAC) and ondemand oxygen therapy, the observation group used BuXu TongBi prescription and on-demand oxygen therapy, the course was three months, they were followed for three months. To compare six-minutes walking distance, life quality,TCM syndrome scores, the scores of difficult breathing and single item of cough and the changes of pulmonary function between both groups. Results: Th observation group was superior to the control group in prolonging six minutes walking distance, improving dyspnea and cough, and the observation group could stabilize pulmonary function, and no severe adverse reaction happened. Conclusion: BuXu TongBi prescription could raise exercise endurance of IPF patients, improve dyspnea and cough, stabilize pulmonary function with good safety.
引文
[1]Lederer DJ,Martinez FJ.Idiopathic pulmonary fibrosis[J].N Engl J Med,2018,378(19):1811-1823.
[2]T Lancet.New guidelines for idiopathic pulmonary fibrosis[J].Lancet,2015,386(9991):312.
[3]Jo HE,Randhawa S,Corte TJ,et al.Idiopathic pulmonary fibrosis and the elderly:diagnosis and management consideration[J].Drug Aging,2016,33(5):321-334.
[4]Borie R,Juetet A,Beltramo G,et al.Pharmacological management of IPF[J].Respirology,2016,21(4):615-625.
[5]Fernando J,Martinez,David J,et al.Focus onidiopathic pulmonary fibrosis[J].Chest,2018,154(4):978-979.
[6]樊茂蓉,韩克华,王冰,等.通肺络补宗气方对特发性肺间质纤维化患者血清TGF-β、TNF-α、CTGF及PDGF的影响[J].辽宁中医杂志,2017,44(12):2572-2575.
[7]闫玉琴,贾琦,苏惠萍.中医对肺纤维化病因病机的探讨[J].西部中医药,2018,31(12):23-25.
[8]Raghu G,Collard HR,Egan J,et al.An official ATS/ERS/JRS/ALAT statement:idio pathic pulmonary fibrosis:evidence-based guidelines for diagnosis and m anagement[J].Am J Respir Crit Care Med,2011,183(6):788-824.
[9]蔡后荣.2011年特发性肺间质纤维化诊断和治疗循证新指南解读[J].中国呼吸与危重监护杂志,2011,10(4):313-316.
[10]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:14-65.
[11]田德禄.中医内科学[M].北京:人民卫生出版社,2003:368-378.
[12]张心月,贾新华,王立娟,等.从气血变化看肺间质纤维化[J].中医药学报,2012,40(3):56-57.
[13]樊茂蓉,张燕萍,苗青,等.肺间质纤维化的中医发病机制与治则探讨[J].中医杂志,2012,53(3):203-204.
[14]杨景青,张伟.论叶氏“络病理论”治疗肺间质纤维化[J].辽宁中医药大学学报,2013,15(3):118-119.
[15]Willis BC,duBois RM,Borok Z.Epithelial origin of myofibroblasts during fibrosis in the lung[J].Proc Am Thorac Soc,2006,3(4):377-382.
[16]李力,王振兴,张秀,等.健脾活血降气法治疗肺间质纤维化的理论探讨[J].西部中医药,2017,30(7):62-64.
[2]T Lancet.New guidelines for idiopathic pulmonary fibrosis[J].Lancet,2015,386(9991):312.
[3]Jo HE,Randhawa S,Corte TJ,et al.Idiopathic pulmonary fibrosis and the elderly:diagnosis and management consideration[J].Drug Aging,2016,33(5):321-334.
[4]Borie R,Juetet A,Beltramo G,et al.Pharmacological management of IPF[J].Respirology,2016,21(4):615-625.
[5]Fernando J,Martinez,David J,et al.Focus onidiopathic pulmonary fibrosis[J].Chest,2018,154(4):978-979.
[6]樊茂蓉,韩克华,王冰,等.通肺络补宗气方对特发性肺间质纤维化患者血清TGF-β、TNF-α、CTGF及PDGF的影响[J].辽宁中医杂志,2017,44(12):2572-2575.
[7]闫玉琴,贾琦,苏惠萍.中医对肺纤维化病因病机的探讨[J].西部中医药,2018,31(12):23-25.
[8]Raghu G,Collard HR,Egan J,et al.An official ATS/ERS/JRS/ALAT statement:idio pathic pulmonary fibrosis:evidence-based guidelines for diagnosis and m anagement[J].Am J Respir Crit Care Med,2011,183(6):788-824.
[9]蔡后荣.2011年特发性肺间质纤维化诊断和治疗循证新指南解读[J].中国呼吸与危重监护杂志,2011,10(4):313-316.
[10]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:14-65.
[11]田德禄.中医内科学[M].北京:人民卫生出版社,2003:368-378.
[12]张心月,贾新华,王立娟,等.从气血变化看肺间质纤维化[J].中医药学报,2012,40(3):56-57.
[13]樊茂蓉,张燕萍,苗青,等.肺间质纤维化的中医发病机制与治则探讨[J].中医杂志,2012,53(3):203-204.
[14]杨景青,张伟.论叶氏“络病理论”治疗肺间质纤维化[J].辽宁中医药大学学报,2013,15(3):118-119.
[15]Willis BC,duBois RM,Borok Z.Epithelial origin of myofibroblasts during fibrosis in the lung[J].Proc Am Thorac Soc,2006,3(4):377-382.
[16]李力,王振兴,张秀,等.健脾活血降气法治疗肺间质纤维化的理论探讨[J].西部中医药,2017,30(7):62-64.